Symbol List Views
Stock Details
CHARTS
COMPANY NEWS
STOCK ANALYSIS
FUNDAMENTALS
HOLDINGS
Edit Symbol List
Symbol Lookup
TSPT: Stock Quote & Summary Data
2.03%
| Last Sale | |
| Change Net / % |
|
| Best Bid / Ask | |
| 1y Target Est: | N/A |
| Today's High / Low | / |
| Share Volume | |
| 50 Day Avg. Daily Volume | 135,792 |
| Previous Close | $ 5.43 |
| 52 Wk High / Low | $ 15.395 / $ 1.11 |
| Shares Outstanding | 13,114,000 |
| Market Value | $ 69,766,480 |
| Annualized Dividend | N/A |
| Ex Dividend Date | N/A |
| Dividend Payment Date | N/A |
| Current Yield | N/A |
| Beta | -0.08 |
| NASDAQ Official Open Price: | $ 5.35 |
| Date of NASDAQ Official Open Price: | Nov. 20, 2009 |
| NASDAQ Official Close Price: | $ 5.32 |
| Date of NASDAQ Official Close Price: | Nov. 20, 2009 |
Intraday Chart |
| 5d | 1m | 6m | 12m | More Charting |
Have a Question About TSPT?
Ask your question about about Transcept Pharmaceuticals, Inc. (TSPT) by typing it in the box below. You'll get direct responses from other members of the NASDAQ Answers community!
Hot Topics in NASDAQ Answers
The most popular questions & answers in the
NASDAQ Answers Community:
Company Description (as filed with the SEC)
We are a biopharmaceutical company focused on in-licensing, developing and commercializing novel therapies for the treatment of cancer. Our product portfolio features two clinical-stage oncology product candidates with worldwide rights, Asentar™ and AQ4N, each of which is a potential treatment for certain types of cancer. In May 2007, we signed an exclusive worldwide License, Development and Commercialization Agreement, or the Collaboration Agreement, with Schering Corporation, a wholly-owned subsidiary of Schering-Plough Corporation (“Schering”), for the development and commercialization of Asentar™ (the “Collaboration Agreement”) in androgen-independent prostate cancer, or AIPC, earlier stages of prostate cancer, and in other types of cancers, including pancreatic cancer. ... More ...
Links to all Transcept Pharmaceuticals, Inc. (TSPT) Pages
Stock Analysis
Fundamentals
Holdings/Ownership
Company News for TSPT |
||
|
Transcept Pharma Q3 Loss Narrows - RTT News 11/12/2009 6:17PM |
||
|
Transcept Pharmaceuticals Reports Third Quarter 2009 Financial Results - PR Newswire 11/12/2009 4:05PM |
||
|
Transcept Pharmaceuticals Q3 09 Earnings Conference Call At 5:00 PM ET - RTT News 11/12/2009 3:07PM |
||
|
Transcept Pharmaceuticals to Present at Lazard Capital Markets Healthcare Conference on November 17 - PR Newswire 11/10/2009 4:05PM |
||
|
Transcept Pharmaceuticals to Report Third Quarter 2009 Results and Host Conference Call on November 12 - PR Newswire 11/05/2009 5:34PM |
||
|
Transcept Pharmaceuticals Receives Notice of Allowance for U.S. Patent Application on Intermezzo(R) - PR Newswire 11/04/2009 7:05AM |
||
|
More PML Troubles for Biogen, Elan MS Drug: Biobuzz - TheStreet 10/29/2009 10:25AM |
